Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study

Background and aimsReal-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited. Hence, we evaluated the efficacy and kidney safety of TAF among this population.MethodsA total of 272 HBV-...

Full description

Bibliographic Details
Main Authors: Wenting Peng, Huimin Gu, Da Cheng, Keyu Chen, Cichun Wu, Chuan Jiang, Jinqing Liu, Shifang Peng, Lei Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Microbiology
Subjects:
hepatitis B virus
acute-on-chronic liver failure
tenofovir alafenamide
kidney function
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2023.1185492/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2023.1185492/full

Similar Items